TrinityPoint Wealth’s ADMA Biologics ADMA Stock Holding History

TrinityPoint Wealth’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,841	Closed	-$121K	–	331
2024 Q2	$121K	Buy	+10,841	New	+$90.9K	0.02%	306

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

TrinityPoint Wealth's ADMA Position: Q3 2024 in Review

TrinityPoint Wealth sold out of ADMA Biologics (ADMA) in Q3 2024, closing a stake of 10,841 shares — an estimated $121K sold.

TrinityPoint Wealth first reported a position in ADMA in Q2 2024 and held it in 1 quarter. The position peaked at $121K in Q2 2024. 306 funds tracked by Wall St. Rank hold ADMA as of Q3 2024.

TrinityPoint Wealth reported no remaining ADMA Biologics position as of Q3 2024 after selling out during the quarter.
TrinityPoint Wealth sold 10,841 ADMA Biologics shares in Q3 2024, an estimated $121K.
TrinityPoint Wealth first reported a position in ADMA Biologics in Q2 2024 and held it in 1 quarter.
TrinityPoint Wealth's ADMA Biologics position peaked at $121K in Q2 2024.
306 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2024.

Based on TrinityPoint Wealth's 13F filing for Q3 2024, filed 7 Nov 2024.